What ChondroFiller injection means for hip cartilage damage

ChondroFiller — also marketed as Liquid Cartilage — reaches the hip joint through an outpatient injection, not an operating theatre. The same CE-marked collagen scaffold that surgeons have placed arthroscopically can now be delivered under local anaesthetic during a clinic appointment, with the patient going home the same day.

The product arrives in a dual-chamber syringe. As the two solutions leave the tip together, they begin to mix and, within roughly three to five minutes inside the joint, set into a stable, gel-like cushion that moulds itself to the contours of the damaged area. No donor cells are added and no biopsy is taken beforehand — the scaffold is entirely acellular. Once in place, it works through acellular matrix-induced chondrogenesis: the collagen framework draws in the patient's own progenitor cells from surrounding tissue, supporting the body's own repair processes rather than substituting for them.

That distinction matters clinically. The injection functions as a top-down collagen cushion laid over worn cartilage surfaces — a different therapeutic role from the bottom-up structural rebuilding attempted via open surgery. Because the delivery mechanism differs, so do the assessment criteria: the injection route carries its own candidacy considerations, which are broader in practice than the strict parameters applied to the arthroscopic surgical series.

Which patients are usually assessed for this injection

Candidacy for ChondroFiller hip injection divides broadly into two clinical pictures, though the boundary between them is less fixed than the surgical literature might suggest.

The first group comprises younger, active patients — often in their thirties or forties — with a discrete, full-thickness cartilage lesion on the acetabulum. These defects frequently arise from cam-type femoroacetabular impingement (FAI), where abnormal contact between the femoral head and acetabular rim progressively damages the anterosuperior cartilage surface. Left unaddressed, such lesions can advance to wider joint degeneration. For this group, the scaffold is deposited directly over a defined focal defect during the injection appointment.

The second group includes patients with more diffuse hip wear — Kellgren-Lawrence Grade III or IV changes across a broader area of the joint — for whom arthroscopy would be disproportionate or unsuitable. Because the injection applies the collagen scaffold as a top-down cushion over worn surfaces rather than anchoring it into a surgically prepared site, it can offer supportive coverage in cases where damage is too extensive for the strict lesion criteria applied in the published arthroscopic series (isolated defects greater than 2 cm², Tönnis Grade 0–1). This wider candidacy is a product of the different delivery mechanism, not an indication that the injection is appropriate for all stages of hip degeneration.

No biopsy or cell harvesting is required for either group, which removes a significant barrier for patients who prefer to avoid an operating theatre. Before any injection is planned, MRI remains the standard pre-assessment step: it characterises defect depth and location, and helps identify pathology — such as advanced bone loss — that falls outside the injection's scope. Individual suitability is determined through clinical assessment.

Why the hip joint needs imaging guidance at all

Reaching the hip joint with a needle is not straightforward anatomy. The femoral head and acetabulum sit well behind thick layers of muscle and adipose tissue; a needle of approximately 7 cm is typically required to arrive at the anterior joint recess. That depth alone rules out the landmark-and-feel approach routinely used for more superficial joints.

The proximity of the femoral neurovascular bundle compounds the problem. The femoral artery, vein, and nerve run immediately anterior to the joint capsule — precisely where an anterior approach must travel. Advancing a needle through this corridor without real-time imaging carries a meaningful risk of vascular puncture or nerve contact, both of which can cause serious harm.

Ultrasound resolves both challenges simultaneously. A high-frequency probe placed over the anterior hip lets the operator identify the femoral neck and anterior recess, trace the course of the femoral vessels, and keep the needle tip continuously in view from skin entry to the target point — all before a single millilitre of material is deposited. Because no ionising radiation is involved, ultrasound is the preferred guidance modality for outpatient use over fluoroscopy or CT, without meaningful loss of accuracy.

Published data support this approach at scale. Byrd and colleagues' 'Nashville Sound' technique, validated across thousands of consecutive hip injection cases, demonstrated that ultrasound guidance is reliable, superior to fluoroscopy in patient satisfaction, and associated with a minimal learning curve for trained practitioners — a finding that has helped establish in-clinic ultrasound-guided injection as the standard for this procedure.

What the ultrasound-guided injection appointment involves

The whole procedure typically takes around 15 to 30 minutes in the clinic — no overnight admission, no sedation, and no theatre preparation is required.

On the treatment table, lying supine, the patient first receives a local anaesthetic along the planned needle path. This numbs the skin and the underlying soft tissues; many patients report feeling little beyond a mild sense of pressure at the front of the hip as the needle subsequently approaches the joint capsule.

The clinician positions the ultrasound probe over the anterior hip, confirms the location of the anterior recess, and traces the femoral vessels before introducing the needle. Its entire shaft remains visible on screen as it travels to the target point — the operator watches the tip continuously and can confirm safe clearance of the vessels before releasing any material into the joint.

Once the needle tip is correctly placed, the ChondroFiller is delivered. Some patients notice a brief sensation of fullness or mild pressure at the front of the hip as the collagen material occupies the joint space and begins to set; this typically settles within a few minutes.

A short period of rest in the clinic follows. Before leaving, the treating clinician discusses appropriate activity levels and any post-injection guidance, personalised to the individual's clinical situation.

What the clinical evidence shows — and where gaps remain

The strongest peer-reviewed evidence for ChondroFiller in the hip comes from a 26-patient arthroscopic cohort published in the Journal of Hip Preservation Surgery in 2021 (PMC8322278). That study confirmed injectable ChondroFiller as a viable one-step procedure for full-thickness acetabular cartilage defects and reported promising functional results — establishing a meaningful clinical reference point for this indication.

Outcome data from published multi-joint cohorts add further detail. Hip patients show approximately a 30-point improvement on the modified Harris Hip Score (mHHS), a validated measure of pain and functional capacity. Across those broader cohorts, 70–85% of treated patients report significant pain relief and measurable improvement in mobility — a figure that spans knee, hip, and small-joint studies rather than a single hip-only randomised controlled trial, and therefore carries moderate rather than definitive confidence. MRI follow-up using the MOCART score — a standardised measure of cartilage fill and surface quality — has returned values of 70–87 across published series. The adverse event rate across available data sits at approximately 0.06%.

Two gaps in the evidence base are worth naming plainly. No published randomised controlled trial has directly compared arthroscopic delivery of ChondroFiller with the injection route in the hip, meaning the relative merits of each delivery method remain an open clinical question. Separately, outcome data for the hip injection route specifically do not yet extend beyond two years, leaving the durability of benefit at longer follow-up uncharacterised.

For patients weighing their options, this is the picture: a substantive early evidence base, with the longer-term follow-up studies still under way.

Finding a specialist and questions worth asking

ChondroFiller hip injection sits within the practice of consultant orthopaedic surgeons and sports medicine physicians who combine hip expertise with image-guided injection experience — the two competencies are inseparable for a procedure that requires placing a collagen scaffold accurately into the anterior recess while tracking a needle past the femoral vessels in real time. Patients researching suitable clinicians will find that UK-wide specialist directories, searchable by region and clinical area, can identify practitioners who list this intervention among their offered treatments.

Four questions are worth taking to any initial consultation:

• Given my defect size and Kellgren-Lawrence grade, am I a candidate for the injection route specifically?
• Is an up-to-date MRI required before proceeding, or does existing imaging suffice?
• What activity restrictions apply in the weeks after injection, and when is return to sport or higher-impact activity realistic?
• What outcomes are plausible for my hip — and over what timeframe should I expect to notice change?

For patients with known cam-type femoroacetabular impingement, one additional question carries particular weight: whether the bony morphology needs to be addressed before or alongside cartilage treatment, since an unresolved cam lesion continues to exert mechanical stress on a repaired surface.

Expectations are worth calibrating at the outset. As the evidence reviewed above shows, functional improvement on validated hip scores builds over weeks to months rather than days — and the injection supports the body's own repair processes rather than delivering instant structural restoration. Not every patient presenting with hip cartilage damage will be a candidate: defect characteristics, hip geometry, and overall joint status all bear on that determination, which a specialist assessment with current imaging is best placed to make.